Mounting evidence has indicated that NF-κB is frequently abnormally activated in many diseases, such as cancer, diabetes and arthritis [24], which has led to the identification of more than 700 NF-κB inhibitors. This evidence concerns the gene NFKB1 and arthritic joint disease.